CA3192515A1 - Viral inhibitors - Google Patents

Viral inhibitors

Info

Publication number
CA3192515A1
CA3192515A1 CA3192515A CA3192515A CA3192515A1 CA 3192515 A1 CA3192515 A1 CA 3192515A1 CA 3192515 A CA3192515 A CA 3192515A CA 3192515 A CA3192515 A CA 3192515A CA 3192515 A1 CA3192515 A1 CA 3192515A1
Authority
CA
Canada
Prior art keywords
mole
substituted
group
amphiphilic
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3192515A
Other languages
English (en)
French (fr)
Inventor
Ijeoma Uchegbu
Andreas Schatzlein
Krzysztof Pyrc
Aleksandra MILEWSKA
Emilia BARRETO DURAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomerics Ltd
Original Assignee
Nanomerics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2013221.3A external-priority patent/GB202013221D0/en
Priority claimed from GBGB2019097.1A external-priority patent/GB202019097D0/en
Priority claimed from GBGB2105404.4A external-priority patent/GB202105404D0/en
Application filed by Nanomerics Ltd filed Critical Nanomerics Ltd
Publication of CA3192515A1 publication Critical patent/CA3192515A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3192515A 2020-08-24 2021-08-24 Viral inhibitors Pending CA3192515A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2013221.3 2020-08-24
GBGB2013221.3A GB202013221D0 (en) 2020-08-24 2020-08-24 Viral inhibitors
GB2019097.1 2020-12-03
GBGB2019097.1A GB202019097D0 (en) 2020-12-03 2020-12-03 Viral inhibitors
GBGB2105404.4A GB202105404D0 (en) 2021-04-15 2021-04-15 Viral inhibitors
GB2105404.4 2021-04-15
PCT/GB2021/052199 WO2022043678A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Publications (1)

Publication Number Publication Date
CA3192515A1 true CA3192515A1 (en) 2022-03-03

Family

ID=77655566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3192515A Pending CA3192515A1 (en) 2020-08-24 2021-08-24 Viral inhibitors

Country Status (8)

Country Link
US (1) US20230330132A1 (https=)
EP (1) EP4199937A1 (https=)
JP (1) JP2023538449A (https=)
CN (1) CN116367843A (https=)
AU (1) AU2021333748A1 (https=)
CA (1) CA3192515A1 (https=)
MX (1) MX2023002109A (https=)
WO (1) WO2022043678A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3194032A1 (en) * 2020-09-04 2022-03-10 The University Of Chicago Materials and methods of treating viral infection with amphiphilic block copolymers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
CN100577179C (zh) * 2003-05-08 2010-01-06 天津帝士力投资控股集团有限公司 甲壳素和壳聚糖及其衍生物在制备抗病毒剂中的应用
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
GB0615834D0 (en) 2006-08-09 2006-09-20 Univ Glasgow Polymeric micellar clusters and their uses in formulating drugs
JP6028968B2 (ja) * 2012-02-24 2016-11-24 学校法人順天堂 抗インフルエンザウイルス剤
PL225045B1 (pl) * 2012-05-18 2017-02-28 Univ Jagiellonski Zastosowanie polimeru chitozanowego do wytwarzania leków do leczenia i profilaktyki infekcji wywołanych przez koronawirusy
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
WO2020039463A1 (en) * 2018-08-23 2020-02-27 Haskoli Islands Chitosan derivatives and methods for preparing the same

Also Published As

Publication number Publication date
CN116367843A (zh) 2023-06-30
MX2023002109A (es) 2023-07-13
WO2022043678A1 (en) 2022-03-03
EP4199937A1 (en) 2023-06-28
JP2023538449A (ja) 2023-09-07
US20230330132A1 (en) 2023-10-19
AU2021333748A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Ucar et al. A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2
JP7510181B2 (ja) 殺ウイルス性ナノ粒子及びインフルエンザウイルスに対するその使用
JP2010537997A (ja) 二機能性ポリマーに結合させたインフルエンザウイルス阻害剤
JP2016503030A (ja) 医薬組成物
US12239629B2 (en) Methods for the prophylaxis and treatment of COVID and COVID-19
JP2023515202A (ja) 免疫抑制薬を含む合成ナノキャリアを使用する方法および組成物
Chintapula et al. A novel nanocomposite drug delivery system for SARS-CoV-2 infections
CA3192515A1 (en) Viral inhibitors
WO2023213310A1 (zh) 调节细胞膜跨膜运输和流动性的碳链物质、制备及应用
WO2022026622A2 (en) Treatment of viral diseases
EP4475868A2 (en) Methods and compositions for treating covid infections
US20230256049A1 (en) Materials and methods for the prevention and treatment of viral respiratory diseases
WO2021236626A1 (en) Mucoretentive antiviral technologies
EP4556028A1 (en) Functionalized nanoparticles for viral clearance
Shi et al. Research Progress in Nanopharmaceuticals with different delivery routes in the antivirus field
Jones et al. Small molecule antivirals to nanoparticles: The need of the hour to combat pandemics
Bai et al. Nanoscale Advances
WO2025240286A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
JP2025510540A (ja) 官能化ナノクラスター及び細菌感染症の治療におけるそれらの使用
CN121401419A (zh) 针对vdac1靶点的物质在制备产品中的应用以及防治由rsv引起的疾病的药物

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240821

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250730

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260209